West Virginia University Logo

WVU CANCER INSTITUTE (WVUCI) PILOT PROJECT GRANTS (PPG)

Deadline for submission of all WVUCI PPG applications is Monday, Oct 3, 2016 (5:00 PM).

The WVU Cancer Institute and Office of Research and Graduate Education announce the availability of the availability of three pilot award funding mechanisms: the American Cancer Society (ACS), supported Pilot Project Grants (PPG), the “Let the Journey Begin” CNS Malignancy focused PPG and the “Phillip M. Dino Innovative Research Fund” PPG, with applications due Monday, Oct 3, 2016

APPLICANT ELIGIBILITY


Applicants may include faculty from the Schools of Medicine, Dentistry, Nursing, Pharmacy, Public Health, or other WVU Schools and Colleges.  Prior membership in the WVU Cancer Institute/Mary Babb Randolph Cancer Center is not necessary, however those with proposals selected will need to submit an application for membership prior to distribution of funds.


Applicants for the “Let the Journey Begin” CNS malignancy focused PPG or “Phillip M. Dino Innovative Research Fund” PPG may be at any academic rank.  


As stated in the ACS Institutional Research Grant (IRG) policy and guidelines, IRG PPGs are intended to support independent, self-directed investigators early in their careers. These individuals (usually at the rank of assistant professor or equivalent) must be eligible to apply for independent national competitive research grants, but may not currently hold such a grant. Applicants for the ACS PPGs should be within six years of their first independent research or faculty appointment as aligned with specific ACS guidelines. Strong preference will be given to those applicants who have not received prior support from the ACS.  Recipients of IRG PPGs must be, at the time of the application, citizens or noncitizen nationals of the United States, or must have been lawfully admitted to the United States for permanent residence. 


Full Announcement

 

ABOUT THE PROJECTS

SCOPE OF ACS IRG PROJECTS

Projects must be relevant to the overall goals of the WVU Cancer Institute and its research programs of emphasis (including, but not limited to the following): mechanisms of metastasis and therapeutic response, breast cancer, hematological malignancies/bone marrow transplantation, tobacco use etiology/prevention or treatment, lung cancer, GI cancers, health outcomes or services research, cancer-focused populations/cancer health disparities research, and experimental therapeutics. Each proposal must be presented in the context of a project that is slated for submission for extramural support. Of the potential applications to be funded, one will be supported in the area of cancer control/prevention in medically underserved patients, an identified interest of the ACS and the WVUCI. For the latter RFA, projects must address areas of special interests specifically identified by ACS, including psychosocial and behavioral research, health policy or health services research, cancer in the poor and medically underserved, or childhood cancer.
Application

 

SCOPE OF “LET THE JOURNEY BEGIN” CNS MALIGNANCY PROJECTS

Projects must be relevant to either primary adult brain tumors or brain metastases secondary to other adult malignancies and can include, but are not limited to: investigations of biomarkers to predict CNS metastasis; microenvironment determinants of therapeutic response; innovative therapeutic approaches for treatment of primary and secondary CNS malignancies; and fundamental mechanistic research related to CNS tumor biology on a broad scale. Proposals must be presented in the context of a project that has the potential to be competitive for subsequent extramural support. Projects with clear translational potential and inclusion of collaborative partnerships will be favorably reviewed. 
Application

 

SCOPE OF “PHILLIP M. DINO” PROJECTS

Projects must involve issues pertaining to smoking cessation in cancer patients and may entail either traditional hypothesis testing or evaluations of changes in practice.  Fundable projects must include some type of patient engagement.  Patient input must be a component which includes review of final study design, conduct, evaluation, and translation to policy/practice changes (if applicable).  Such input should occur prior to application and, if possible, as part of a formal plan post award, including translation and dissemination to non-academic audiences.
Application